Cantor Fitzgerald Reduces Stake in Bristol Myers Squibb

Institutional investor trims position in pharmaceutical giant

Apr. 11, 2026 at 8:38am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up of the complex gears, valves, and machinery that make up the manufacturing infrastructure of a major pharmaceutical company.An inside look at the industrial machinery powering the production of life-saving pharmaceuticals.Princeton Today

Cantor Fitzgerald Investment Advisors L.P. reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 10.6% during the 4th quarter, according to the company's recent SEC filing. The fund now owns 259,133 shares of the biopharmaceutical company's stock, valued at $13.98 million.

Why it matters

This filing provides insight into the investment strategy of Cantor Fitzgerald, a major institutional investor, and their view on the prospects of Bristol Myers Squibb, a leading pharmaceutical company. Tracking changes in institutional ownership can offer clues about market sentiment and future stock performance.

The details

According to the SEC filing, Cantor Fitzgerald Investment Advisors sold 30,582 shares of Bristol Myers Squibb during the fourth quarter. The firm's total holdings in the company are now valued at $13.98 million. Bristol Myers Squibb is a global biopharmaceutical company focused on developing and delivering medicines for serious diseases in areas like oncology, hematology, immunology, and cardiovascular disease.

  • The filing covers the 4th quarter of 2025.

The players

Cantor Fitzgerald Investment Advisors L.P.

A major institutional investment firm that has reduced its stake in Bristol Myers Squibb.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the shifting investment strategies of major institutional players like Cantor Fitzgerald as they evaluate the prospects of pharmaceutical giants like Bristol Myers Squibb. Tracking these changes in ownership can provide valuable insights into market sentiment and potential future stock performance.